Gan & Lee Pharmaceuticals.

XSSC:603087 Stock Report

Market Cap: CN¥26.9b

Gan & Lee Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Gan & Lee Pharmaceuticals's earnings have been declining at an average annual rate of -34%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been declining at an average rate of 7.4% per year. Gan & Lee Pharmaceuticals's return on equity is 5.2%, and it has net margins of 19.7%.

Key information

-34.0%

Earnings growth rate

-36.4%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate-7.4%
Return on equity5.2%
Net Margin19.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Gan & Lee Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSSC:603087 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,9475811,339535
30 Jun 242,6935051,211506
31 Mar 242,6103871,183514
31 Dec 232,6083401,179501
30 Sep 232,3812411,177539
30 Jun 232,107-1081,231580
31 Mar 231,580-5041,270585
31 Dec 221,712-4401,361562
30 Sep 222,3461681,375517
30 Jun 222,9718821,364496
31 Mar 223,7531,3761,425485
31 Dec 213,6121,4531,321475
30 Sep 213,6731,4161,312486
30 Jun 213,6301,2961,290456
31 Mar 213,4411,2981,244418
31 Dec 203,3621,2311,196420
30 Sep 203,2341,1921,164363
30 Jun 203,1441,2071,151332
31 Mar 202,9371,1931,043266
31 Dec 192,8951,1671,076236
31 Dec 182,387934956143
31 Dec 172,3711,080765137
31 Dec 161,7717707090
31 Dec 151,2204475840
31 Dec 149273054910
31 Dec 136932053850

Quality Earnings: 603087 has a large one-off gain of CN¥174.9M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 603087's current net profit margins (19.7%) are higher than last year (10.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603087's earnings have declined by 34% per year over the past 5 years.

Accelerating Growth: 603087's earnings growth over the past year (141.3%) exceeds its 5-year average (-34% per year).

Earnings vs Industry: 603087 earnings growth over the past year (141.3%) exceeded the Biotechs industry 1.3%.


Return on Equity

High ROE: 603087's Return on Equity (5.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 06:07
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gan & Lee Pharmaceuticals. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhu ChenCitic Securities Co., Ltd.
Shitong HanCitic Securities Co., Ltd.
Tianyi YanGoldman Sachs